$232.77
4.31%
NYSE, Nov 18, 03:59 pm EST. Closed.

Glaukos Corp Stock price

$233.08
+66.12 39.60% 1M
+90.90 63.93% 6M
+120.17 106.43% YTD
+141.44 154.34% 1Y
+169.16 264.64% 3Y
+185.88 393.81% 5Y
+199.89 602.26% 10Y
+201.86 646.57% 20Y
NYSE, Closing price Wed, Nov 18 2026
-10.17 4.18%

Is Glaukos Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,090 stocks worldwide.

Key metrics

Basic
Market capitalization
$14.4b
Enterprise Value
$14.1b
Net debt
positive
Cash
$336.7m
Shares outstanding
59.2m
Valuation
P/E
negative
P/S | estimate
20.9 | 18.4
EV/Sales | estimate
20.5 | 18.0
EV/FCF | ex SBC
392.3 | negative
P/B
20.1
Financial Health
Equity Ratio
73.4%
Return on Equity
-28.6%
ROCE
-7.3%
ROIC
-
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$83.1m | 12.0%
SBC as % of FCF
230.6%
SBC Growth 1Y
40.2%
Share Count Growth 1Y
3.1%
Shareholder Yield
-3.1%
Financials
Revenue | estimate
$690.3m | $783.8m
EBITDA
$-15.5m
EBIT
$-61.8m
Net Income
$-169.8m
Free Cash Flow | ex SBC
$36.0m | $-47.1m
Growth
Revenue | estimate
46.9% | 54.5%
EBITDA
68.6%
EBIT
30.1%
Net Income
-93.8%
Free Cash Flow
181.5%
Margin
Gross
81.1%
EBITDA
-2.3%
EBIT
-9.0%
Net
-24.6%
Free Cash Flow | ex SBC
5.2% | -6.8%
More
EPS
$-2.8
FCF per Share
$0.6
Short interest
9.2%
Employees
1k
Rev per Employee
$460.0k

Glaukos Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Glaukos Corp forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a Glaukos Corp forecast:

Buy
90%
Hold
10%

Glaukos Corp Events

Past Events
OCT
28
Q3 2026 Earnings Call
21 days ago
JUL
29
Q2 2026 Earnings Call
4 months ago
APR
29
Q1 2026 Earnings Call
7 months ago
FEB
17
Q4 2025 Earnings Call
9 months ago
JAN
13
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
3
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
11
UBS Global Healthcare Conference 2025
about one year ago
OCT
29
Q3 2025 Earnings Call
about one year ago

Financial data from Glaukos Corp

Sep '26
+/-
%
690 690
47% 47%
100%
- Direct Costs 130 130
20% 20%
19%
560 560
55% 55%
81%
- Selling and Administrative Expenses 435 435
42% 42%
63%
- Research and Development Expense 187 187
30% 30%
27%
-16 -16
69% 69%
-2%
- Depreciation and Amortization 46 46
19% 19%
7%
EBIT (Operating Income) EBIT -62 -62
30% 30%
-9%
Net Profit -170 -170
94% 94%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about Glaukos Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Glaukos Corp Stock News

Neutral
PRNewsWire
●
19 days ago
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, November 4: S&P MidCap 400 constituent Okta Inc. (NASD: OKTA) will replace Kenvue Inc. (NYSE: KVUE) in the S&P 500, S&P SmallCap 600 constituent Glaukos Corp. (NYSE: GKOS) will replace Okta in the S...
Neutral
Business Wire
●
21 days ago
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include: Record net sales of $211.0 million in Q3 2026 increased 58% ...
More Glaukos Corp News

Company Profile

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Head office United States
CEO Mr. Burns
Employees 1,094
Founded 1998
Website www.glaukos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today